CN117769540A - 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式 - Google Patents
4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式 Download PDFInfo
- Publication number
- CN117769540A CN117769540A CN202280034492.9A CN202280034492A CN117769540A CN 117769540 A CN117769540 A CN 117769540A CN 202280034492 A CN202280034492 A CN 202280034492A CN 117769540 A CN117769540 A CN 117769540A
- Authority
- CN
- China
- Prior art keywords
- compound
- crystalline form
- cancer
- solvent
- slurry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187125P | 2021-05-11 | 2021-05-11 | |
| US63/187,125 | 2021-05-11 | ||
| PCT/US2022/028606 WO2022240886A1 (en) | 2021-05-11 | 2022-05-10 | Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117769540A true CN117769540A (zh) | 2024-03-26 |
Family
ID=81854861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280034492.9A Pending CN117769540A (zh) | 2021-05-11 | 2022-05-10 | 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240228438A1 (https=) |
| EP (1) | EP4337638A1 (https=) |
| JP (1) | JP2024518429A (https=) |
| CN (1) | CN117769540A (https=) |
| TW (1) | TW202308991A (https=) |
| WO (1) | WO2022240886A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013005165A (es) * | 2010-11-10 | 2013-07-05 | Theravance Inc | Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico. |
| CA2991020A1 (en) * | 2015-07-07 | 2017-01-12 | Japan Tobacco Inc. | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
| EP3381896B1 (en) * | 2015-11-27 | 2023-01-18 | Taiho Pharmaceutical Co., Ltd. | Biphenyl compound or salt thereof |
| AU2017385958B2 (en) * | 2016-12-28 | 2021-12-02 | Tonix Pharma Holdings Limited | Tianeptine oxalate salts and polymorphs |
| WO2021095835A1 (en) * | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
-
2022
- 2022-05-10 EP EP22726922.2A patent/EP4337638A1/en not_active Withdrawn
- 2022-05-10 CN CN202280034492.9A patent/CN117769540A/zh active Pending
- 2022-05-10 WO PCT/US2022/028606 patent/WO2022240886A1/en not_active Ceased
- 2022-05-10 US US18/560,360 patent/US20240228438A1/en active Pending
- 2022-05-10 JP JP2023568486A patent/JP2024518429A/ja active Pending
- 2022-05-10 TW TW111117524A patent/TW202308991A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024518429A (ja) | 2024-05-01 |
| EP4337638A1 (en) | 2024-03-20 |
| WO2022240886A1 (en) | 2022-11-17 |
| TW202308991A (zh) | 2023-03-01 |
| US20240228438A1 (en) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI874490B (zh) | 三苯化合物之新穎鹽類 | |
| KR102683492B1 (ko) | 엘로빅시바트의 결정수식 | |
| JP6756617B2 (ja) | Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 | |
| CN117769540A (zh) | 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式 | |
| KR20170032330A (ko) | Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도 | |
| BRPI1008396B1 (pt) | composto de sal de tosilato de um derivado de 5-pirazolil-2-piridona, composição farmacêutica, uso e processo para preparação do dito composto | |
| CN104918937B (zh) | 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途 | |
| CN111278808B (zh) | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 | |
| CN103889971B (zh) | (1，1-二氧代-4-硫代吗啉基)-[6-[[3(4-氟苯基)-5-甲基-4-异噁唑基]甲氧基]-3-吡啶]-甲酮的固体形式 | |
| JP2021523120A (ja) | セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態 | |
| CN113840605B (zh) | N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途 | |
| KR102858471B1 (ko) | Lta4h 저해제의 결정질 형태 | |
| HK40108981A (zh) | 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式 | |
| CN112823161B (zh) | 共晶体及其用途 | |
| WO2014177011A1 (zh) | 二氢吲哚酮衍生物的二马来酸盐及其多晶型物 | |
| CN114685492B (en) | Crystal form of TAS-116, preparation method, pharmaceutical composition and application thereof | |
| WO2015074281A1 (zh) | 力格赛狄盐及其晶型、它们的制备方法和用途 | |
| RU2802964C2 (ru) | Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида | |
| HK40076742A (en) | Novel salt of terphenyl compound | |
| WO2026086860A1 (zh) | At2受体抑制剂的盐、其固体形式及其制备方法和用途 | |
| TW202543633A (zh) | 喹唑啉酮衍生物的晶型及其製備方法和應用 | |
| WO2022144042A1 (zh) | Tas-116的晶型及其制备方法、药物组合物和用途 | |
| CN120058671A (zh) | 沃诺拉赞半富马酸盐及其制备方法 | |
| HK40076742B (zh) | 新型三苯基化合物盐 | |
| HK40020497A (en) | Crystalline solid forms of salts, processes for making, and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40108981 Country of ref document: HK |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20250708 Address after: Tokyo, Japan Applicant after: Dapeng Oncology Co.,Ltd. Country or region after: Japan Applicant after: Dapeng Pharmaceutical Industry Co.,Ltd. Address before: California, USA Applicant before: AstraZeneca Pharmaceuticals Country or region before: U.S.A. Applicant before: Dapeng Pharmaceutical Industry Co.,Ltd. Country or region before: Japan |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20250716 Address after: Tokyo, Japan Applicant after: Dapeng Pharmaceutical Industry Co.,Ltd. Country or region after: Japan Address before: Tokyo, Japan Applicant before: Dapeng Oncology Co.,Ltd. Country or region before: Japan Applicant before: Dapeng Pharmaceutical Industry Co.,Ltd. |